Patients, customers and distributors are being notified and should refer to Patients may receive either EpiPen Auto-Injector or the authorized generic for EpiPen Auto-Injector at the pharmacy as a replacement based on availability. The authorized generic has the exact same drug formulation, has the exact same operating instructions and is therapeutically equivalent to EpiPen Auto Injector, and may be substituted for EpiPen Auto Injector.It is important that patients continue to carry their current EpiPen Auto-Injector until they receive a replacement device. is 8082708 and it has a September 2020 expiration date.According to the recall notice, Mylan has notified its distributors and customers about the recall by letter and is arranging for return of all recalled products.
The recall is for Alprazolam 0.5 mg tablets that were distributed in July and August 2019 in 500-count bottles.
EpiPen (epinephrine injection, USP) and EpiPen Jr® (epinephrine injection, USP) Auto-InjectorsAn official website of the United States government:
The expanded voluntary recall is being initiated in the U.S. and also will extend to additional markets in Europe, Asia, North and South America.The recall impacts the 0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector. Mylan NV said on Tuesday it is expanding a nationwide voluntary recall of its blood pressure medicine valsartan to include all lots, two weeks after it recalled select batches.
Mylan Pharmaceuticals is voluntarily recalling one lot of the anti-anxiety prescription drug Alprazolam nationwide because of “the potential presence of a foreign substance,” according to a recall notice posted on "Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk of infection to a patient cannot be ruled out," the notice states.
FDA does not endorse either the product or the company.Mylan N.V. (NASDAQ, TASE: MYL) today announced that Meridian Medical Technologies, a Pfizer company and Mylan's manufacturing partner for EpiPen® Auto-Injector, has expanded a voluntary recall of select lots of EpiPen (epinephrine injection, USP) and EpiPen Jr® (epinephrine injection, USP) Auto-Injectors to now include additional lots distributed in the U.S. and other markets in consultation with the U.S. Food and Drug Administration (FDA).This recall is being conducted as a result of the receipt of two previously disclosed reports outside of the U.S. of failure to activate the device due to a potential defect in a supplier component. HERTFORDSHIRE, England and PITTSBURGH, Dec. 4, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. Recalls, Market Withdrawals, & Safety Alerts
The affected drug's lot No. Consumers with questions should call Mylan at 800-796-9526, Monday through Friday, 8 a.m. to 5 p.m. Eastern time, or email at The medicine is for the management of anxiety disorder, the short-term relief of symptoms of anxiety, and the treatment of panic disorder, with or without agoraphobia, according to Mylan.© 2020 USA TODAY, a division of Gannett Satellite Information Network, LLC. "The recall is for Alprazolam 0.5 mg tablets that were distributed in July and August 2019 in 500-count bottles. Delays in epinephrine administration have been associated with negative health consequences. However, the recall is being expanded to include additional lots as a precautionary measure out of an abundance of caution.The recalled product was manufactured by Meridian Medical Technologies, a Pfizer company, and distributed by Mylan Specialty between December 2015 and July 2016. BACKGROUND: The expanded voluntary recall is being initiated in the U.S. and also will extend to additional markets in Europe, Asia, North and South America.